Open AccessClinical Application of <em>Sleeping Beauty</em> and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
Author(s) -
M. Helen Huls,
Matthew J. Figliola,
Margaret J. Dawson,
Simon Olivares,
Partow Kebriaei,
Elizabeth J. Shpall,
Richard E. Champlin,
Harjeet Singh,
Laurence J.N. Cooper
Publication year - 2013
Publication title -
journal of visualized experiments
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 91
ISSN - 1940-087X
DOI - 10.3791/50070
Subject(s) - biology , genetically modified organism , genetic enhancement , chimeric antigen receptor , antigen , transposase , transgene , retrovirus , microbiology and biotechnology , immunology , immunotherapy , virology , transposable element , gene , immune system , virus , genetics , genome
e50070, doi:10.3791/50070 (2013). The potency of clinical-grade T cells can be improved by combining gene therapy with immunotherapy to engineer a biologic product with the potential for superior (i) recognition of tumor-associated antigens (TAAs), (ii) persistence after infusion, (iii) potential for migration to tumor sites, and (iv) ability to recycle effector functions within the tumor microenvironment. Most approaches to genetic manipulation of T cells engineered for human application have used retrovirus and lentivirus for the stable expression of CAR1-3. This approach, although compliant with current good manufacturing practice (GMP), can be expensive as it relies on the manufacture and release of clinical-grade recombinant virus from a limite
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom